Clinical trials: Movement Abnormalities
Dementia With Lewy Bodies
Expanded Access Program for CT1812 (Zervimesine)
This is a multi-center, open label, expanded access program (EAP) that will provide 100 mg CT1812 for up to one year to participants with mild-to-moderate DLB.
- Trial name
- NCT06961760
- Testing
- zervimesine
- Where
- 8 sites in United States
- Sponsor
- Cognition Therapeutics
Parkinson's Disease
Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease
The primary objective of the study is to evaluate the clinical efficacy of BIIB054 via dose response using the change from baseline in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Total Score.
- Trial name
- SPARK (NCT03318523)
- Testing
- BIIB054
- Where
- 75 sites in United States, Austria and 7 more
- Volunteers
- 357 people
- Sponsor
- Biogen
Parkinson Disease
PK Study in Patients With Parkinson's Disease With IZD174
Single center, open-label, intra-individual dose-escalation study in subjects with mild/moderate Parkinson's Disease
- Trial name
- NCT04338997
- Testing
- IZD174
- Sponsor
- Inflazome UK Ltd
Movement Disorders (Incl Parkinsonism)
Correlation of Motor Metrics and Neurological Data
This is a pilot study to collect data with the Ceraxis product and standard movement disorders tests in order to prove and codify potential correlations.
- Trial name
- COMMAND (NCT05462080)
- Testing
- Ceraxis product
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Ceraxis Health, Inc
Tourette Syndrome
Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents
This study evaluates the effect of ecopipam tablets in children and adolescents in the treatment of Tourette's Syndrome (TS). Half of the participants will receive ecopipam tablets, while the other half will receive matching…
- Trial name
- D1AMOND (NCT04007991)
- Testing
- Ecopipam
- Where
- 70 sites in United States, Canada and 3 more
- Volunteers
- 153 people
- Sponsor
- Emalex Biosciences Inc.
Parkinson's Disease
Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease
The purpose of this study is to assess the safety and efficacy of long-term use of Duodopa in patients with Parkinkon's disease in actual usage
- Trial name
- NCT02906488
- Where
- 127 sites in Japan
- Volunteers
- 839 people
- Sponsor
- AbbVie
Parkinson's Disease
Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations
The primary objective of the study is to compare the adhesiveness of two different patch formulations of rotigotine using patch size 40 cm2, under the assumption that both patch formulations show similar adhesiveness properties.
- Trial name
- NCT01338896
- Testing
- Rotigotine transdermal patch
- Where
- 16 sites in Austria, Germany and 1 more
- Volunteers
- 56 people
- Sponsor
- UCB Pharma
Parkinson's Disease
Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients
Patients with Parkinson's disease who completed the prior double-blind study 6002-009 are eligible to enter into this long-term study.
- Trial name
- 6002-010 (NCT00957203)
- Testing
- Istradefylline
- Where
- Japan
- Volunteers
- 308 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson's Disease, Essential Tremor
Movement Disorder Quantification Algorithm Development
The purpose of this study is to collect kinematic motion data from subjects with movement disorders such as Parkinson's disease (PD) and essential tremor (ET) to develop and validate algorithms for quantifying motor symptoms such…
- Trial name
- NCT01534650
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Huntington's Disease
A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease
This is a first-in-human, multi-center trial studying the effects of SRP-1005 in participants with Huntington's disease (HD).
- Trial name
- NCT07536061
- Testing
- SRP-1005
- Where
- 5 sites in Australia, New Zealand and 2 more
- Volunteers
- 32 people
- Sponsor
- Sarepta Therapeutics, Inc.
Parkinson's Disease
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
To establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the percentage of OFF time in patients with advanced Parkinson's disease (PD) treated with levodopa.
- Trial name
- NCT00199355
- Testing
- Istradefylline (KW-6002)
- Where
- Japan
- Volunteers
- 75 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Wilson Disease
A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease
The primary objectives of this study are to evaluate the safety of single IV doses of UX701 in patients with Wilson disease, to select the UX701 dose with the best benefit/risk profile based on the totality of safety and efficacy…
- Trial name
- NCT04884815
- Testing
- UX701, Standard of Care (SOC)
- Where
- 16 sites in United States, Portugal and 2 more
- Volunteers
- 82 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Health Volunteers, Huntington Disease
A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease
The purpose of this study is to demonstrate engagement of pridopidine with S1R and D2R (optional) in the living human brain. No formal statistical analysis will be conducted
- Trial name
- NCT03019289
- Testing
- pridopidine (90 mg)
- Where
- Germany
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Prilenia
Parkinson's Disease
Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease
Parkinson's disease (PD) is a neurological condition, which means it affects the brain. This study will evaluate how ABBV-951 is absorbed under the skin of participants with PD when administered to arm, thigh and flank compared…
- Trial name
- NCT05094050
- Testing
- ABBV-951
- Where
- 10 sites in United States
- Volunteers
- 16 people
- Sponsor
- AbbVie
Parkinson Disease, Depression
Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
Parkinsons Disease (PD) is caused by a decrease of dopamine in a particular part of the brain. Dopamine is a messenger substance (neurotransmitter) that is used by the cells of the brain (nerve cells) to control and harmonize…
- Trial name
- NCT00297778
- Testing
- Pramipexole
- Where
- 77 sites in Austria, Finland and 11 more
- Volunteers
- 296 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
Eligible participants, who participated in the ADAGIO trial and who sign an approved informed consent form, will be enrolled into the study at their original study locations.
- Trial name
- NCT00936676
- Testing
- rasagiline mesylate
- Where
- 102 sites in United States, Argentina and 11 more
- Volunteers
- 684 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Parkinson's Disease
A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).
This is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease.
- Trial name
- NCT00974974
- Testing
- IPX066, IR CD-LD
- Where
- 73 sites in United States, Canada and 6 more
- Volunteers
- 471 people
- Sponsor
- Impax Laboratories, LLC
Early Stage Parkinson's Disease
An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
This is a multicenter, 6 months open label safety extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.001 trial
- Trial name
- NCT00332917
- Testing
- Pardoprunox
- Where
- 130 sites in United States, Argentina and 19 more
- Volunteers
- 224 people
- Sponsor
- Solvay Pharmaceuticals
Parkinson, Parkinson Disease
A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops® Relative to INBRIJA®
Patients with Parkinson's disease (PD) are commonly treated with a combination of levodopa and a decarboxylase inhibitor (DCI). However, many PD patients experience motor fluctuations (OFF episodes), even with their regular…
- Conditions
- Parkinson, Parkinson Disease, Parkinson's Disease and Parkinsonism
- Trial name
- NCT06037590
- Testing
- Levodopa Cyclops®, INBRIJA®
- Where
- Bulgaria
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- PureIMS B.V.
Essential Tremor, Parkinson Disease
Symptomatic Relief of Action Tremor With Cala Trio Using Trio+ Bands
Demonstrate safety and effectiveness of symptomatic action tremor relief in the treated hand following stimulation with the Cala Trio System using the Trio+ bands as compared to the Trio bands in adults with Essential Tremor (ET)…
- Trial name
- NCT05480215
- Testing
- Cala Device
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Cala Health, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.